BUENA, N.J., June 19, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted another abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to four, with fifteen submissions now pending at the FDA.
Jason Grenfell-Gardner, President and CEO of the Company, commented, "After this submission, we have now filed seventeen ANDA filings since the end of 2010, and we have fifteen pending approval and on file with the FDA. We are on track to meet our goal of at least ten ANDA submissions in 2014. This is our third submission this month, and we still plan to add to our pending submissions this week. We believe our current pipeline of submissions pending approval by the FDA has a combined addressable market of over $420 million based on recent data from IMS Health."
About IGI Laboratories,
Inc.IGI Laboratories is a generic topical pharmaceutical company. We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.
For further information: Jenniffer Collins, IGI Laboratories, Inc.,
(856) 697-4379, www.igilabs.com